News & Events
The information in our press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.
SEATTLE, April 22, 2021 — Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today announced the pricing of its…
READ MORE
Leonard S. Paolillo Appointed as Chief Commercial Officer, Gerald F. Penn Appointed as Vice President, Market Access & Trade Significant Leadership Experience Continues Build Out of Impel’s Commercial Strategy, Infrastructure and Market Access Capabilities as Company Advances Go-To-Market Strategy for…
READ MORE
Impel adopting Veeva software, data, and consultingto accelerate pre-launch planning and digital-first commercial execution SEATTLE and PLEASANTON, CA — February 10, 2021 — Impel NeuroPharma and Veeva Systems (NYSE: VEEV) today announced a strategic partnership as Impel continues advancing its…
READ MORE
FDA Conditionally Accepts Trade Name, TRUDHESA™, Pending Approval of the NDA, and Sets PDUFA Goal Date of September 6, 2021 Company’s Lead Candidate is Based on Impel’s Proprietary Precision Olfactory Delivery (POD®) Technology, and is the First and Only Delivery…
READ MORE
~The INP104 New Drug Application is Supported by Results from the Phase 3 STOP 301 Study~ ~Dihydroergotamine mesylate (DHE) is Administered via Impel’s Proprietary Precision Olfactory Delivery (POD®) Technology, the First and Only Delivery System to Utilize the Vascular-Rich Upper…
READ MORE
66.3% of Patients Reported Pain Relief Within Two Hours of Treatment with Rapid Uptake via the Upper Nasal Space Resulting in Onset of Relief as Early as 15 Minutes for Some Patients Data Suggest Use of Impel’s Proprietary Precision Olfactory…
READ MORE
Study Shows INP105 Achieves Rapid Absorption Which May Provide An Effective, Convenient, & Noninvasive Future Alternative for Treating Acute Agitation In the Home, Community, or Hospital Setting INP105 is a Powder Formulation of Olanzapine, the Gold Standard Treatment for Acute…
READ MORE
Four Scientific Poster Presentations Support the Potential of INP104 to Fulfill Key Unmet Needs and If Approved, Become a Transformative New Therapeutic Option for Acute Migraine Additional Data from STOP 301, the Company’s Pivotal Phase 3 Study of INP104 for…
READ MORE
Exploratory Efficacy Data Reveal INP104 Resulted in Pain Relief in 66.3% of Patients and Pain Freedom in 38% of Patients at Two Hours After First Dose; Additionally, 16.3% of Patients Reported They Gained Initial Relief as Early as 15 Minutes…
READ MORE
SEATTLE, May 5, 2020 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced an expanded role of…
READ MORE
